Search - tctmd.com

Displaying 21 - 40 of 53

Sort: Relevancy | Date

Leaflet Thickening and Impaired Motion No Worse With TAVR: PARTNER 3 CT

News Conference News TCT 2019

Leaflet Thickening and Impaired Motion No Worse With TAVR: PARTNER 3 CT

Michael O'Riordan

September 27, 2019

Oral Anticoagulation Post-AVR Safe but Not Routinely Needed: PARTNER II

News Daily News

Oral Anticoagulation Post-AVR Safe but Not Routinely Needed: PARTNER II

August 27, 2019

TAVR Bleeds Stand Apart From PCI-Related Events

News Daily News

TAVR Bleeds Stand Apart From PCI-Related Events

August 06, 2019

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

News Conference News TVT 2019

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

Michael O'Riordan

June 13, 2019

Potential Warning Signs Seen for NOAC Use After TAVR

News Daily News

Potential Warning Signs Seen for NOAC Use After TAVR

June 12, 2019

New Leaflet Thrombosis After TAVR Seen Out to 3 Years: OCEAN-TAVI

News Daily News

New Leaflet Thrombosis After TAVR Seen Out to 3 Years: OCEAN-TAVI

February 19, 2019

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

News Daily News

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

January 09, 2019

The Biggest News of 2018: TCTMD’s Top 10

News Daily News

The Biggest News of 2018: TCTMD’s Top 10

December 31, 2018

Complications Following TAVR Are Going Down, US Data Show

News Conference News AHA 2018

Complications Following TAVR Are Going Down, US Data Show

Yael L. Maxwell

November 20, 2018

News Opinion Conversations in Cardiology

Conversations in Cardiology: Can a Patient With Tissue Valves Switch From Warfarin to a NOAC?

November 16, 2018

TCTMD’s Top 10 Most Popular Stories for October 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2018

October 31, 2018

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

October 12, 2018

GALILEO Trial of Rivaroxaban After TAVR Stopped Early for Harm

News Daily News

GALILEO Trial of Rivaroxaban After TAVR Stopped Early for Harm

October 09, 2018

Atrial Fibrillation, Oral Anticoagulation Linked With Mortality After TAVR: FRANCE-TAVI

News Conference News ESC 2018

Atrial Fibrillation, Oral Anticoagulation Linked With Mortality After TAVR: FRANCE-TAVI

Michael O'Riordan

August 25, 2018

New Review Probes Possibility of CVD Prevention Without Aspirin

News Daily News

New Review Probes Possibility of CVD Prevention Without Aspirin

Michael O'Riordan

July 04, 2018

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

News Daily News

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

Michael O'Riordan

June 20, 2018

Ticagrelor: Better Platelet Blockade Post-TAVR?

News Conference News CRT 2018

Ticagrelor: Better Platelet Blockade Post-TAVR?

Michael O'Riordan

March 07, 2018

Predicting the Future: Will the Ongoing GALILEO and ENVISAGE AF Trials Change How We Anticoagulate Patients After TAVR?

Presentation TCT 2017

Predicting the Future: Will the Ongoing GALILEO and ENVISAGE AF Trials Change How We Anticoagulate Patients After TAVR?

Presenter: David H. Adams, Ted Feldman, Vinod H. Thourani

October 30, 2017

Clinical Leaflet Thrombosis After TAVR Tied to Cardiogenic Shock and Death

News Conference News ESC 2017

Leaflet Thrombosis After TAVR Tied to Cardiogenic Shock and Death

Yael L. Maxwell

September 01, 2017

Valve Leaflet Thrombosis: Treat It or Leave It Be?

News Conference News TVT 2017

Valve Leaflet Thrombosis: Treat It or Leave It Be?

June 19, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.